Results 151 to 160 of about 9,892 (240)

Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan

, 2019
Motoh Iwasa, Tomoaki Ishihara, Michio Kato, Ayako Isoai, Ryosuke Kobayashi, Naoko Torii, Noriko Soneda, Yoshiyuki Takei   +7 more
openalex   +2 more sources

Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure　― A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial ―

, 2021
Naoki Sato, Shingo Uno, Yumiko Yamasaki, Takahiro Hirano, Seongryul Kim, on behalf of the OPC-61815 Investigators   +5 more
openalex   +2 more sources

Tolvaptan versus other interventions for hyponatraemia in people with cirrhosis. [PDF]

Cochrane Database Syst Rev
Anila KN, Saraswathy NS, Mohamed ZU, Varghese CT, Binoj ST, Gopalakrishnan U, Balakrishnan D, Valsan A, Sudhindran S.   +8 more
europepmc   +1 more source

Safety and Efficacy of Tolvaptan for Acute Refractive Hyponatremia Associated with Traumatic Brain Injury. [PDF]

J Clin Med
Desai S, Holsaeter K, Winski A, Barletta JF, Bauer F.   +4 more
europepmc   +1 more source

SP032TWO YEARS EXPERIENCE OF TOLVAPTAN TREATMENT FOR TWENTY-THREE ADPKD PATIENTS [PDF]

, 2016
Shinsuke Nomura, Mayumi Endo, Hiroshi Matsuo   +2 more
openalex   +1 more source

Prognostic impact of the acute reactiveness to intravenous administration of tolvaptan sodium phosphate in patients with acute decompensated heart failure. [PDF]

Eur Heart J Open
Ouchi S, Iwata H, Moriya S, Naito R, Takahashi N, Kasai T, Minamino T.   +6 more
europepmc   +1 more source

A Case of Refractory Syndrome of Inappropriate Secretion of Antidiuretic Hormone Accompanying Small Cell Lung Cancer Successfully Treated with Tolvaptan

, 2013
Katsuyoshi Tomomatsu, Tsuyoshi Oguma, Hiromi Tomomatsu, Tetsuya Urano, Koichiro Asano, Tadashi Abe   +5 more
openalex   +2 more sources

Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease

, 2022
Javier Naranjo, Francisco Borrego, José Luis Rocha, Mercedes Salgueira, Adoración Martín-Gómez, Cristhian Orellana, A Morales, Fernando Vallejo, Pilar Hidalgo, Francisca Rodríguez, Remedios Garófano, Isabel González, Rafael José Esteban de la Rosa, Mario Espinosa   +13 more
openalex   +1 more source

Relcovaptan: a promising therapeutic agent in traumatic spinal cord injury that acts by modulating newly identified transcriptional regulators of aquaporins compared to tolvaptan. [PDF]

Turk J Med Sci
Iş Ş, Ceman D, Iş M, Keser N, Tekin Ş.   +4 more
europepmc   +1 more source

Hiponatrémia: diagnóstico e tratamento [PDF]

, 2012
Inês Raposo Vieira da Silva
core